tiprankstipranks
Trending News
More News >

United Therapeutics price target lowered to $330 from $350 at JPMorgan

JPMorgan analyst Jessica Fye lowered the firm’s price target on United Therapeutics (UTHR) to $330 from $350 and keeps an Overweight rating on the shares. The firm sees the upcoming Phase III TETON 2 data for Tyvaso in idiopathic pulmonary fibrosis as a key event for the stock. The readout offers “significantly more upside than downside,” the analyst tells investors in a research note.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1